Physician profile
Taral Patel
NPI 1790419364
$1,124.46
in general payments reported to CMS, 2019-2025
9 companies · $966 in 2025
The $966 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $55.78 · 2023: $77.39 · 2024: $25.59 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643 · Consulting Fee: $400 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.09 |
| Consulting Fee | $400.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $400.00 | 2025 | Acuvue |
| Glaukos Corporation | $148.79 | 2025 | |
| Alcon Vision LLC | $133.52 | 2022-2025 | Total30, Dailies Total1, Precision 1 |
| Bausch & Lomb Americas INC. | $125.89 | 2025 | Miebo, Xiidra |
| Abbvie INC. | $100.93 | 2022-2023 | |
| Coopervision INC. | $90.55 | 2025 | Clariti Contact Lens |
| Genentech USA, INC. | $80.54 | 2025 | |
| Rxsight INC | $25.59 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Novartis Pharmaceuticals Corporation | $18.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taral Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.